anti-APRIL (mouse), mAb (rec.) (blocking) (Apry-1-3)
|Synonyms||A Proliferation Inducing Ligand; TNFSF13; CD256; TALL-2|
|Product Type||Recombinant Antibody|
|Source/Host||Produced without the use of animals. Purified from HEK 293 cell culture supernatant.|
|Immunogen/Antigen||Mouse APRIL (aa 98-232).|
Recognizes mouse APRIL. Does not recognize mouse BAFF.
|Purity Detail||Protein A-affinity purified.|
|Endotoxin Content||<0.01EU/μg purified protein (LAL-test; Lonza)|
|Formulation||Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.|
|Other Product Data||
APRIL (mouse) monoclonal antibody (recombinant) (blocking) (APRY-1-3) is composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the human lgG1 Fc domain.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Stable for at least 1 month after receipt when stored at +4°C.
Stable for at least 1 year after receipt when stored at -20°C.
|Product Specification Sheet|
APRIL is a cytokine that belongs to the TNF superfamily and binds to TACI and BCMA. It is implicated in the regulation of tumor cell growth and is involved in monocyte/macrophage-mediated immunological processes.
Anti-APRIL (mouse) Monoclonal Antibody (recombinant) (Blocking) (APRY-1-3) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.